Clinical, Virological, and Biological Parameters Associated with Outcomes of Ebola Virus Infection in Macenta, Guinea

The pathogenesis of Ebola virus (EBOV) disease (EVD) is poorly characterized. The establishment of well-equipped diagnostic laboratories close to Ebola treatment centers (ETCs) has made it possible to obtain relevant virological and biological data during the course of EVD and to assess their association with the clinical course and different outcomes of the disease. We were responsible for diagnosing EBOV infection in patients admitted to two ETCs in forested areas of Guinea. The pattern of clinical signs was recorded, and an etiological diagnosis was established by RT-PCR for EBOV infection or a rapid test for malaria and typhoid fever. Biochemical analyses were also performed. We handled samples from 168 patients between November 29, 2014, and January 31, 2015; 97 patients were found to be infected with EBOV, with coinfection in 18%. Overall mortality for EVD cases was 58%, rising to 86% if . was also present. Viral load was higher in fatal cases of EVD than in survivors, and fatal cases were associated with higher aspartate aminotransferase (AST) and alanine aminotransferase (ALT), C-reactive protein (CRP), and IL-6 levels. Furthermore, regardless of outcome, EVD was characterized by higher creatine kinase (CPK), amylase, and creatinine levels than in febrile patients without EVD, with higher blood urea nitrogen (BUN) levels in fatal cases of EVD only. These findings suggest that a high viral load at admission is a marker of poor EVD prognosis. In addition, high AST, ALT, CRP, and IL-6 levels are associated with a fatal outcome of EVD. Damage to the liver and other tissues, with massive rhabdomyolysis and, probably, acute pancreatitis, is associated with EVD and correlated with disease severity. Finally, biochemical analyses provide substantial added value at ETCs, making it possible to improve supportive rehydration and symptomatic care for patients. The French Ministry of Foreign Affairs, the Agence Française de Développement, and Institut Pasteur.

Citing Articles

C-reactive protein and association with disease severity in hospitalized adult patients with Lassa fever in Nigeria.

Dic-Ijiewere E, Asogun D, Okojie F, Omono A, Christopher O, Zumla A IJID Reg. 2025; 14:100506.

PMID: 39877415 PMC: 11772983. DOI: 10.1016/j.ijregi.2024.100506.

RNA Viruses, Toll-Like Receptors, and Cytokines: The Perfect Storm?.

Stegeman S, Kourko O, Amsden H, Pellizzari Delano I, Mamatis J, Roth M J Innate Immun. 2025; 17(1):126-153.

PMID: 39820070 PMC: 11845175. DOI: 10.1159/000543608.

Efficacy and Immunogenicity of a Recombinant Vesicular Stomatitis Virus-Vectored Marburg Vaccine in Cynomolgus Macaques.

Camargos V, Rossi S, Juelich T, Smith J, Vasilakis N, Freiberg A Viruses. 2024; 16(8).

PMID: 39205155 PMC: 11359148. DOI: 10.3390/v16081181.

Rhabdomyolysis, Acute Kidney Injury, and Mortality in Ebola Virus Disease: Retrospective Analysis of Cases From the Eastern Democratic Republic of the Congo, 2019.

Kasereka M, Mukadi-Bamuleka D, Kitenge-Omasumbu R, Edidi-Atani F, Kuamfumu M, Mulangu S J Infect Dis. 2024; 230(2):e465-e473.

PMID: 38696335 PMC: 11326845. DOI: 10.1093/infdis/jiae224.

Derivation and Internal Validation of a Mortality Prognostication Machine Learning Model in Ebola Virus Disease Based on Iterative Point-of-Care Biomarkers.

Bearnot C, Mbong E, Muhayangabo R, Laghari R, Butler K, Gainey M Open Forum Infect Dis. 2024; 11(2):ofad689.

PMID: 38379568 PMC: 10878059. DOI: 10.1093/ofid/ofad689.

References

Baize S . Ebola virus in West Africa: new conquered territories and new risks-or how I learned to stop worrying and (not) love Ebola virus. Curr Opin Virol. 2015; 10:70-6. DOI: 10.1016/j.coviro.2015.01.008. View

Gignoux E, Azman A, De Smet M, Azuma P, Massaquoi M, Job D . Effect of Artesunate-Amodiaquine on Mortality Related to Ebola Virus Disease. N Engl J Med. 2016; 374(1):23-32. DOI: 10.1056/NEJMoa1504605. View

Chatzizisis Y, Misirli G, Hatzitolios A, Giannoglou G . The syndrome of rhabdomyolysis: complications and treatment. Eur J Intern Med. 2008; 19(8):568-74. DOI: 10.1016/j.ejim.2007.06.037. View

Villinger F, Rollin P, Brar S, Chikkala N, Winter J, Sundstrom J . Markedly elevated levels of interferon (IFN)-gamma, IFN-alpha, interleukin (IL)-2, IL-10, and tumor necrosis factor-alpha associated with fatal Ebola virus infection. J Infect Dis. 1999; 179 Suppl 1:S188-91. DOI: 10.1086/514283. View

Leroy E, Baize S, Volchkov V, Fisher-Hoch S, Georges-Courbot M, Capron M . Human asymptomatic Ebola infection and strong inflammatory response. Lancet. 2000; 355(9222):2210-5. DOI: 10.1016/s0140-6736(00)02405-3. View

Cournac J, Karkowski L, Bordes J, Aletti M, Duron S, Janvier F . Rhabdomyolysis in Ebola Virus Disease. Results of an Observational Study in a Treatment Center in Guinea. Clin Infect Dis. 2015; 62(1):19-23. DOI: 10.1093/cid/civ779. View

Maruo N, Morita I, Shirao M, Murota S . IL-6 increases endothelial permeability in vitro. Endocrinology. 1992; 131(2):710-4. DOI: 10.1210/endo.131.2.1639018. View

Deen G, Broutet N, Xu W, Knust B, Sesay F, McDonald S . Ebola RNA Persistence in Semen of Ebola Virus Disease Survivors - Final Report. N Engl J Med. 2015; 377(15):1428-1437. PMC: 5798881. DOI: 10.1056/NEJMoa1511410. View

Sissoko D, Laouenan C, Folkesson E, MLebing A, Beavogui A, Baize S . Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea. PLoS Med. 2016; 13(3):e1001967. PMC: 4773183. DOI: 10.1371/journal.pmed.1001967. View

10.

Rollin P, Bausch D, Sanchez A . Blood chemistry measurements and D-Dimer levels associated with fatal and nonfatal outcomes in humans infected with Sudan Ebola virus. J Infect Dis. 2007; 196 Suppl 2:S364-71. DOI: 10.1086/520613. View

11.

Baize S, Leroy E, Georges A, Georges-Courbot M, Capron M, Bedjabaga I . Inflammatory responses in Ebola virus-infected patients. Clin Exp Immunol. 2002; 128(1):163-8. PMC: 1906357. DOI: 10.1046/j.1365-2249.2002.01800.x. View

12.

Schibler M, Vetter P, Cherpillod P, Petty T, Cordey S, Vieille G . Clinical features and viral kinetics in a rapidly cured patient with Ebola virus disease: a case report. Lancet Infect Dis. 2015; 15(9):1034-1040. DOI: 10.1016/S1473-3099(15)00229-7. View

13.

Mate S, Kugelman J, Nyenswah T, Ladner J, Wiley M, Cordier-Lassalle T . Molecular Evidence of Sexual Transmission of Ebola Virus. N Engl J Med. 2015; 373(25):2448-54. PMC: 4711355. DOI: 10.1056/NEJMoa1509773. View

14.

Agarwal N, Pitchumoni C . Acute pancreatitis: a multisystem disease. Gastroenterologist. 1993; 1(2):115-28. View

15.

Schieffelin J, Shaffer J, Goba A, Gbakie M, Gire S, Colubri A . Clinical illness and outcomes in patients with Ebola in Sierra Leone. N Engl J Med. 2014; 371(22):2092-100. PMC: 4318555. DOI: 10.1056/NEJMoa1411680. View

16.

Takahashi S, Metcalf C, Ferrari M, Moss W, Truelove S, Tatem A . Reduced vaccination and the risk of measles and other childhood infections post-Ebola. Science. 2015; 347(6227):1240-2. PMC: 4691345. DOI: 10.1126/science.aaa3438. View

17.

Sow M, Etard J, Baize S, Magassouba N, Faye O, Msellati P . New Evidence of Long-lasting Persistence of Ebola Virus Genetic Material in Semen of Survivors. J Infect Dis. 2016; 214(10):1475-1476. DOI: 10.1093/infdis/jiw078. View

18.

Walker P, White M, Griffin J, Reynolds A, Ferguson N, Ghani A . Malaria morbidity and mortality in Ebola-affected countries caused by decreased health-care capacity, and the potential effect of mitigation strategies: a modelling analysis. Lancet Infect Dis. 2015; 15(7):825-32. PMC: 4824180. DOI: 10.1016/S1473-3099(15)70124-6. View

19.

Aylward B, Barboza P, Bawo L, Bertherat E, Bilivogui P, Blake I . Ebola virus disease in West Africa--the first 9 months of the epidemic and forward projections. N Engl J Med. 2014; 371(16):1481-95. PMC: 4235004. DOI: 10.1056/NEJMoa1411100. View

20.

Barry M, Toure A, Traore F, Sako F, Sylla D, Kpamy D . Clinical predictors of mortality in patients with Ebola virus disease. Clin Infect Dis. 2015; 60(12):1821-4. DOI: 10.1093/cid/civ202. View